Nuvectis Pharma Inc (NVCT) Hedge Fund Ownership (Q2 2026)

Nuvectis Pharma Inc (NVCT)

82 + Investors. Track Smart Money conviction in NVCT. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — NVCT

Based on 84 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added NVCT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

84 hedge funds hold NVCT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +79% more funds vs a year ago

fund count last 6Q

+37 new funds entered over the past year (+79% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 74% buying

65 buying23 selling

Last quarter: 65 funds were net buyers (32 opened a brand new position + 33 added to an existing one). Only 23 were sellers (14 trimmed + 9 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+16 vs last Q)

new funds entering per quarter

Funds opening a new NVCT position: 11 → 4 → 16 → 32. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

📌

Mixed — 30% long-term, 48% new

■ 30% conviction (2yr+) ■ 23% medium ■ 48% new

Of the 84 current holders: 25 (30%) held >2 years, 19 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💰

Value +462% but shares only +136% — price-driven

Value

+462%

+136%

Last quarter: the total dollar value of institutional holdings rose +462%, but actual share count only changed +136%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

20 → 11 → 4 → 16 → 32 new funds/Q

New funds entering each quarter: 11 → 4 → 16 → 32. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

📊

Mixed cohorts — 39% veterans, 51% new entrants

■ 39% veterans ■ 10% 1-2yr ■ 51% new

Of 90 current holders: 35 (39%) held 2+ years, 9 held 1–2 years, 46 (51%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 23% AUM from major funds

23% from top-100 AUM funds

25 of 82 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

5.1

out of 10

Moderate Exit Risk

Exit risk score 5.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	82	61	34.43%
13F Shares	11M	5M	136.37%
Total Value	$197M	$35M	462.37%
New Positions	32	16	+16
Increased Positions	33	19	+14
Closed Positions	9	4	+5
Reduced Positions	11	10	+1
Total Calls	5	1	400.0%
Total Puts	3	0	100%
PUT/CALL Ratio	0.6	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

34.43%

13F Shares

11M

136.37%

Total Value

$197M

$35M

462.37%

New Positions

+16

Increased Positions

+14

Closed Positions

Reduced Positions

Total Calls

400.0%

Total Puts

100%

PUT/CALL Ratio

0.6

0.0

Bullish

Institutional Holders (2026 Q2)

82 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NVCT. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 NVCT holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Iridian Asset Management LLC/Ct	4.91%	777,078	$14.3M
2	Occam Crest Management LP	3.84%	357,147	$7.4M
3	Kalehua Capital Management LLC	1.32%	100,000	$1.8M
4	Tang Capital Management LLC	1.29%	1,550,000	$28.5M
5	Sphera Funds Management LTD.	0.92%	382,945	$7.0M
6	Soleus Capital Management, L.P.	0.63%	1,000,000	$18.4M
7	Avidity Partners Management LP	0.59%	200,000	$3.7M
8	Baldwin Wealth Partners LLC/Ma	0.46%	382,015	$7.0M
9	Stonepine Capital Management, LLC	0.34%	40,000	$736K
10	Perceptive Advisors LLC	0.28%	1,000,000	$18.4M
11	Squadron Capital Management LLC	0.22%	38,700	$712K
12	Forbes J M & Co LLP	0.09%	59,000	$1.1M
13	Austin Wealth Management, LLC	0.08%	20,125	$385K
14	Informed Momentum Co LLC	0.08%	47,168	$867K
15	DAFNA Capital Management LLC	0.07%	20,000	$368K
16	Shay Capital LLC	0.02%	21,000	$386K
17	Avalon Trust Co	0.02%	14,000	$257K
18	Oppenheimer & Co Inc	0.01%	73,566	$1.4M
19	Caption Management, LLC	0.01%	160,300	$2.9M
20	Alyeska Investment Group, L.P.	0.01%	275,000	$5.1M
21	Martingale Asset Management L P	0.01%	18,024	$331K
22	Lanark Financial, INC.	0.01%	6,000	$110K
23	Strs Ohio	0.00%	27,200	$500K
24	CIBC Bancorp USA Inc.	0.00%	67,155	$918K
25	MetLife Investment Management, LLC	0.00%	9,652	$178K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Nuvectis Pharma Inc (NVCT)

What does the Smart Money Trend signal show for NVCT?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added NVCT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NVCT?

More buyers than sellers — 74% buying: Last quarter: 65 funds were net buyers (32 opened a brand new position + 33 added to an existing one). Only 23 were sellers (14 trimmed + 9 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NVCT holders?

Strong quality — 23% AUM from major funds: 25 of 82 holders rank in the top 100 by AUM, accounting for 23% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held NVCT?

Mixed — 30% long-term, 48% new: Of the 84 current holders: 25 (30%) held >2 years, 19 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Nuvectis Pharma Inc (NVCT)

Smart Money Signals — NVCT

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +79% more funds vs a year ago

More buyers than sellers — 74% buying

More new buyers each quarter (+16 vs last Q)

Mixed — 30% long-term, 48% new

Value +462% but shares only +136% — price-driven

Acceleration phase — new buyers rushing in

Mixed cohorts — 39% veterans, 51% new entrants

Strong quality — 23% AUM from major funds

Institutional Sentiment Summary — NVCT

Hedge Fund Ownership: NVCT

Market Analysis: NVCT

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: NVCT

Hedge Fund Positioning: NVCT

Statistics: NVCT

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Nuvectis Pharma Inc (NVCT)

Welcome to 13Foresight!